Literature DB >> 624273

Mannosidosis: separation and characterization of two acid alpha-mannosidase forms in mutant fibroblasts.

B K Burton, H L Nadler.   

Abstract

Two acidic forms of alpha-mannosidase activity, A and B, are separated and characterized in fibroblasts from controls and patients with mannosidosis. In normal cells, A and B differ in adsorption on DEAE-cellulose, electrophoretic mobility, stability at 70 degrees C and resistance to freezing at --20 degrees C. In 5 of 6 mutant cell lines, A and B both exhibit altered Km's for artificial substrates and decreased thermal stability. Zn2+ has no effect on A or B in mutant or normal cells. In contrast, Co2+ slightly inhibits B in normal cells but markedly enhances the activity of B in mutant cells. The mutation in mannosidosis clearly results in an alteration in the biochemical characteristics of both major acidic forms of alpha-mannosidase.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 624273     DOI: 10.1159/000458546

Source DB:  PubMed          Journal:  Enzyme        ISSN: 0013-9432


  4 in total

1.  Characterization of alpha-mannosidase in feline mannosidosis.

Authors:  S Raghavan; G Stuer; L Riviere; J Alroy; E H Kolodny
Journal:  J Inherit Metab Dis       Date:  1988       Impact factor: 4.982

2.  Residual mannosidase activity in human mannosidosis: characterization of the mutant enzyme.

Authors:  L Poenaru; C Miranda; J C Dreyfus
Journal:  Am J Hum Genet       Date:  1980-05       Impact factor: 11.025

3.  Apparently normal extracellular acidic alpha-mannosidase in fibroblast cultures from patients with mannosidosis.

Authors:  Y Ben-Yoseph; C L DeFranco; J Charrow; L C Hahn; H L Nadler
Journal:  Am J Hum Genet       Date:  1982-01       Impact factor: 11.025

4.  Mucopolysaccharidosis type I subtypes. Presence of immunologically cross-reactive material and in vitro enhancement of the residual alpha-L-iduronidase activities.

Authors:  E H Schuchman; R J Desnick
Journal:  J Clin Invest       Date:  1988-01       Impact factor: 14.808

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.